Late breaking trials of 2016 in coronary artery disease: Commentary covering SCAI, ACC, TCT, EuroPCR, ESC, and AHA.

about

Late breaking trials of 2016 in coronary artery disease: Commentary covering SCAI, ACC, TCT, EuroPCR, ESC, and AHA.

Item

http://www.wikidata.org/entity/Q46724260

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Late breaking trials of 2016 i ...... C, TCT, EuroPCR, ESC, and AHA.

@en

Late breaking trials of 2016 i ...... C, TCT, EuroPCR, ESC, and AHA.

@nl

type

Item

label

Late breaking trials of 2016 i ...... C, TCT, EuroPCR, ESC, and AHA.

@en

Late breaking trials of 2016 i ...... C, TCT, EuroPCR, ESC, and AHA.

@nl

prefLabel

Late breaking trials of 2016 i ...... C, TCT, EuroPCR, ESC, and AHA.

@en

Late breaking trials of 2016 i ...... C, TCT, EuroPCR, ESC, and AHA.

@nl

P1476

Late breaking trials of 2016 i ...... C, TCT, EuroPCR, ESC, and AHA.

@en

P2093

Jennifer A Tremmel

http://www.w3.org/2001/XMLSchema#string

Jordan Safirstein

http://www.w3.org/2001/XMLSchema#string

Payam Dehghani

http://www.w3.org/2001/XMLSchema#string

Saif Anwaruddin

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.

Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.

Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Result

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.

2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.

Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.

Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.

Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.

P304

1028-1034

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CCD.26940

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Binita Shah

Arnold H Seto

P577

2017-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28276150

http://www.w3.org/2001/XMLSchema#string